| Answers |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Loans > Have Collateral? Use It! |
|
Answers - Have Collateral? Use It!
There are primarily two types of loans in the market – secured personal loan and unsecured pers According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product onal loan. The former can be availed by putting up something of value as collateral against the ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in loan amount. These loans are specifically meant for homeowners. Unsecured loans can be procured lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. without the need for the borrower to put up any collateral as security. While unsecured loans here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe are more popular in the UK market as it caters to both homeowners and tenants, secured loans ha d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro e a wide market too. This is because of the numerous benefits attached with these loans. Secur ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc d loans facilitate a big amount for the borrower. The loan range is between ₤5000 to S easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi 56;250,000. The repayment term is between five to twenty-five years. This facilitates better ha nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically dling of the finances and a chance for the borrower to repay the loan amount with a certain pea and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ e of mind. Also, the rate of interest is lower than that of unsecured loans. This is primarily ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ue to the presence of collateral in the case of secured loans. Lenders can recoup the loan amou ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a nt by selling off the collateral in case of a repayment default from the borrower’s side. The dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod resence of collateral that allows for a big amount is in itself something of a bane. Borrowers cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin end to furnish collateral lured by the prospect of big cash. However, most do it without keepin tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen g in mind their repayment capabilities. The year 2006 witnessed a record number of collateral r t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel possessions in the UK. There are several places from where one can get secured loans. There ar ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust banks, building societies, private lenders and the online facilities. Secured loans are proba y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products bly the best options in terms of choice and convenience for the customer. However, even while a . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de ailing these loans, once should do so with a certain amount of discretion and prudence. There a elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip e a lot of unlicensed lenders in the market waiting to take advantage of unsuspecting borrowers tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Management Span of Control and The Power of Models Using Free Web Hosting For Your Business-Sure-Why Not?
|